OBJECTIVE: To review the published literature regarding the effect of caloric restriction, pharmacologic intervention, and exercise to promote the loss of visceral adipose tissue (VAT) DESIGN: A review was conducted of published studies which measured VAT using computed tomography or magnetic resonance imaging before and after caloric restriction, pharmacologic therapy, or exercise. STUDIES REVIEWED: 23 separate studies were reviewed. Men represented 38% and women 63% of the 599 volunteers. There were 17 black volunteers and 30 patients with NIDDM included in these studies. MEASUREMENTS: Data regarding the baseline and change in VAT, body fat, and body weight were collected. RESULTS: Most interventions demonstrated a preferential loss of VAT regardless of the intervention applied. When expressed as percent change in VATapercent change in body fat, a ratio can be calculated which we call the Selectivity Index (SI). When this index is applied to the literature reviewed, two observations can be made. First, the Selectivity Index is higher when baseline body fat is higher. Second, there is a direct relationship between the Selectivity Index and the baseline visceral fat ratio. These two observations suggest that individuals with greater visceral fat mass, either through an increase in the body weight or the propensity to store fat in the visceral depot, lose more visceral fat when adjusted to the loss of body fat. CONCLUSION: In conclusion, the Selectivity Index is useful to compare the ability of an intervention to speci®cally target the loss of AT. This simple index can serve as a benchmark for comparing intervention studies to each other.
Introduction
The amount of visceral adipose tissue (VAT) is closely related to the metabolic complications of obesity. 1 Weight loss, by any means, results in loss of VAT. Pharmacological therapy for obesity, has been suggested to speci®cally target VAT loss, although the number of volunteers studied is very small. 2 This has important implications for obesity therapy, as targeted loss of VAT would be expected to result in a greater reduction in metabolic risk factors such as hyperlipidaemia, insulin resistance and hypertension. As new interventions enter the marketplace, claims will be made regarding the selectivity of a given intervention for VAT loss. As such, an evaluation of the existing literature is needed to place future clinical observations in perspective.
The purpose of this review is threefold: a) to review the literature which has used direct measures of VAT during an intervention such as caloric restriction, pharmacological therapy or exercise. We have limited the studies cited to those which used computed tomography (CT) scanning or magnetic resonance imaging (MRI) to measure VAT. Several excellent reviews and tutorials of these techniques are available and, therefore, they will not be reviewed 3 ; b) an attempt was made to interpret these studies as a whole. Generalizations regarding the type of interventions which are most likely to result in selective loss of VAT can be made only when viewing the entire literature; and c) recommendations are made regarding the appropriate dependent variables to use when planning an intervention trial.
Methods

Data collection
Initially, studies appearing in Medline up to 1 January 1998 were extracted and reviewed. The references, included in each paper, were surveyed for additional papers not detected by the Medline search. All intervention studies which used caloric restriction, pharmacological interventions or exercise, were included if they utilized CT or MRI as a measure of VAT. An effort was made to select locations of imaging that were similar between studies. For example, the 4th ± 5th lumbar vertebral interspace was used when data was available for more than one site.
Data analysis
In order to compare studies, it was ®rst necessary to express the results in common units. Most investigators use single slice CT or MRI to measure a crosssectional area of VAT. Several groups have adopted multislice MRI scanning, to measure volume of VAT, as well as total adipose tissue mass. For those studies which use cross-sectional areas, we elected to convert cross-sectional areas to volumes, and then mass, as several investigators have demonstrated a high correlation between VAT cross-sectional area and VAT volume measured by multi-slice CT or MRI. 4, 5 We used the predictive equations of Kvist et al, 6 to convert cm 2 of 4 ± 5 lumbar VAT to L of VAT. 6 We also acknowledge that, even though the correlation coef®cient between cross-sectional area and volume are high, this calculation introduces some error into our analysis, particularly when non-Caucasian populations are considered. 7 We felt that the conversion in the opposite direction, that is volume (L) to cross sectional area (cm 2 ), was more problematic due to variation in the method used to calculate volume. The volume of VAT was converted to mass by multiplying L of VAT by 0.93 kgaL, the density of adipose tissue.
The visceral to abdominal subcutaneous fat ratio (VaS) was calculated by dividing the baseline VAT in cm 2 by the baseline abdominal subcutaneous area, also in cm 2 . The percent change from baseline, for selected variables was calculated as [(initial 7 ®-nal)ainitial]*100. Study data are presented as the mean values for each subgroup andaor gender, and are presented in Table 1 .
After organizing and reviewing these data, we asked the question,``did caloric restriction, drug therapy, or exercise cause a preferential loss of VAT, when compared to the reduction in total body fat or subcutaneous (non-VAT) fat?'' Because the degree of weight loss, if any, varies widely across the studies reviewed, we attempted to compare studies, by normalizing the amount of VAT lost for the change (D) in fat mass (FM). We refer to this as thè VAT Selectivity Index (SI)'. The index is calculated by dividing the percent change in VAT by the percent change in total body fat. This allows for comparison of the change in VAT relative to the change in total body fat. Ideally, we would have liked to compare the change in VAT with the change in non-VAT, but this is problematic, since it would require a measure of 
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Visceral adipose tissueÐa critical review of intervention strategies SR Smith and JJ Zachwieja total subcutaneous fat. Direct measurement of subcutaneous fat requires multi-slice CT or MRI, or subtracting VAT from total body fat. Each of these procedures is likely to introduce signi®cant measurement error. As such, we feel that by using a direct measurement of subcutaneous adipose tissue is not likely to be a reality in the near future, given currently available technology, and we prefer to normalize VAT loss with the change in total body fat as a practical alternative. To reiterate, an intervention which selectively targets VAT will have a high SI, whereas an intervention which results in loss of only non-VAT adipose tissue will have a low value. Please note that the index refers to only the selectivity of an intervention and not to the magnitude of the VAT loss. For example, an intervention (A) which results in an equal loss of VAT and total adipose tissue, would have a SI of 1.0. A second intervention (B) which results in a two-fold greater loss of VAT, compared to the total adipose tissue loss, would have a SI of 2.0. If the intervention (A) resulted in a 15 kg fat loss and the latter a 5 kg fat loss, intervention A would be preferable to the latter, even though the SI is lower. As such, the authors would reiterate that the SI should be used as an index of preferential VAT loss and combining this index with the absolute or percent loss of VAT will give the utility of a given intervention in patient care.
Overview of collected studies
A total of 23 studies, for a total of 599 volunteers were reviewed (Table 1) . Men represented 38% and women 62% of the whole; 17 Black volunteers were studied and 30 of the 599 volunteers had non insulin-dependent diabetes mellitus (NIDDM). Insuf®cient data was available to construct a meta-analysis. As such, all observations are empirical, rather than based on a strict statistical analysis.
Effects of caloric restriction on VAT loss
Several conclusions can be drawn from the data assembled. First, it appears that the absolute amount of VAT lost depends not only upon the VAT at baseline, but upon the overall degree of fat loss (Figure 1) . Thus, when comparing across dietary interventions, the magnitude of weight or fat loss 
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Visceral adipose tissueÐa critical review of intervention strategies SR Smith and JJ Zachwieja must be considered. We have attempted to correct this by diving the VAT loss by the amount of weight lost and/or the amount of fat lost, when the data was available. By doing this, a correction is introduced for the duration of the therapy, the ef®cacy of the intervention and differences in the amount of excess weight at the start of the intervention. These ratios, the %D VATa%D fat or %DVATaD fat ratio can then be used to compare interventions across study designs. As described in Methods, these are indices of selectivity and do not describe the magnitude of VAT lost. Overall, diet intervention resulted in greater percent VAT loss than percent total fat loss. That is to say, the SI was b 1 in almost all cases. VAT has a higher rate of lipolysis in vitro and presumably increased turnover of fatty acids. As such, it has been proposed that VAT is a`mobile' depot, which allows for energy availability during times of caloric de®cit. 8 This data supports the thrifty gene hypothesis as almost all interventions which result in caloric de®cits cause a greater loss of VAT than total body fat.
9 ± 11 The degree of caloric restriction (low calorie diet (LCD) vs very low calorie diet (VLCD)), which usually parallels the rate of weight loss, does not appear to in¯uence the SI (Table 1) . Figure 2 shows the relationship between VaS ratio at baseline and the SI. VaS ratio has been used as a marker for the propensity to store fat in the visceral depot. There is a clear trend for studies which enroll individuals with a greater VaS ratio, to have preferential loss of visceral fat in relation to total body fat. Considerable overlap is seen between men and women. This suggests that women with a higher VaS ratio behave similarly to men. Men appear to lose more VAT for any given weight loss (average SI for men is 1.75 and for women is 1.3). On the surface, this would suggest that caloric restriction in men targets VAT to a greater extent than women. Figure  2 suggests that this is due to a greater VaS ratio at baseline for men. Others have shown that those individuals with the most VAT, lose the greatest amount of VAT. 12 To date, no studies of suf®cient size have directly compared the response of men to that of women, with regards to percent of VAT loss in relation to the amount of fat lost for a single intervention. A direct comparison between men and Data are means extracted from summary tables or text. D change from baseline, body fat measured by hydrodensitometry, anthropometrics or multislice magnetic resonance imaging (MRI) scanning. The latter was converted to kilograms by multiplying by 0.93 kg/L VAT visceral adipose tissue; VAT in cm 2 was converted to VAT volume using gender speci®c equations as described by Kvist et al. 5 Conversion to kg was accomplished by multiplying by 0.93 kg/L; Abd Abdominal; SAT Subcutaneous adipose tissue; SI selectivity index; FM fat mass; V/S Visceral to subcutaneous ratio; DEX dexfen¯uramine; CR R Caloric restriction plus resistive exercise; Aex Aerobic exercise; Rex Resistive exercise; CR Ex Caloric restriction plus exercise; PreM premenopausal; PostM postmenopausal; NIDDM non-insulin dependent diabetes mellitus; nl normal; B black; W white; SQO subcutaneous obesity; VFO visceral fat obesity; Y young, O older.
Visceral adipose tissueÐa critical review of intervention strategies SR Smith and JJ Zachwieja women with similar VaS ratio would be necessary to resolve the gender question. Matching or randomization of baseline VaS ratio, or inclusion of VaS as a covariate in statistical analysis should be considered in trials which measure VAT loss. In a similar fashion, the degree of fat loss in¯uences the degree of VAT loss (Figure 1 ). There appears from this analysis, to be no real advantage to caloric restriction, when compared to exercise or pharmacological therapy. As discussed below, both pharmacological and exercise interventions have been proposed to be selective for VAT loss. No well controlled studies support these claims, as direct comparisons between interventions are not available.
Pharmacological intervention
Our review of this literature points out that pharmacological intervention does not appear to result in greater % VAT lossa% body fat loss than caloric restriction (LCD or VLCD) regardless of the speci®c agent used. One exception is the study of Marks et al, 13 which differs not only in the derived ratio of % VAT losta% body fat lost, but also in the baseline VaS ratio. At 1.3, the VaS ratio is much higher than other studies, but consistent with a subset of NIDDM individuals seen in our clinical database. As noted previously, the VaS ratio appears to in¯uence the degree of visceral fat loss. Therefore, it is dif®cult to make a conclusion regarding the selectivity of dexfen¯uramine, to cause targeted VAT loss given high VaS ratio at baseline in the Marks study. This issue is unlikely to be resolved, given the withdrawal of dexfen¯uramine from the marketplace.
There is a paucity of studies to directly address the question of pharmacological selectivity and none that compares drug therapy without caloric restriction, to caloric restriction alone. Overall, pharmacological intervention appears to be as effective as caloric restriction to promote VAT loss. Studies which directly compare caloric restriction with pharmacological therapy are needed to directly test this. Again, taking the baseline VaS ratio into consideration, will allow for a better comparison of selectivity for VAT loss. The dif®culties in achieving signi®cant weight loss with non-pharmacological interventions will make direct comparison a dif®cult, if not impossible, task.
Exercise
Exercise has been regarded as a speci®c therapy for visceral fat loss. Exercise has small effects on body weight when used as a monotherapy for obese individuals. Body composition clearly changes, with an increase in lean mass and a decrease in FM.
14 No clear paradigm has formed regarding the most appropriate exercise regime to target VAT mass.
Ross et al, 15 chose to examine exercise as an adjunct to caloric restriction. He found no greater loss of VAT by adding either aerobic exercise or resistance exercise to caloric restriction in men. Treuth et al 16 Visceral adipose tissueÐa critical review of intervention strategies SR Smith and JJ Zachwieja the Treuth or the Despre Âs study compared exercise to caloric restriction alone, limiting a direct comparison.
When we compare the overall SI of studies which utilize exercise, with studies using caloric restriction alone, we ®nd that the average SI is slightly larger with exercise than caloric restriction (2.7 vs 1.5). However, it is our view that there are no clear patterns from the studies surveyed to recommend one form of exercise over another, to promote visceral fat loss. As with the evaluation of pharmacological interventions, we suggest that future studies directly compare exercise with caloric restriction alone.
Implications for planning clinical trials
The world population is aging. Aging has been shown to be associated with increasing amounts of VAT. 18 ± 20 VAT is directly associated with the negative health consequences of obesity. As such, the ability of an intervention to selectively target VAT loss, will become more important in the decades to come. As new therapeutic options enter the marketplace, some mechanism will be necessary to evaluate each one for selective loss of VAT.
Since VAT is highly associated with the majority of the metabolic effects of obesity, therapies which selectively target VAT may be more effective at reducing the complications of obesity. One can therefore make the argument that VAT loss should be included as a dependent variable, when assessing the ability of any intervention to bring about an improvement in the metabolic consequences of obesity. We propose the use of the VAT SI, as a means of comparing treatment effects across studies. The inclusion of careful body composition measurements, speci®cally total body fat, will allow for calculation of the SI within a given study. It was somewhat surprising that a number of the reviewed studies did not measure total body fat (Table 1) . Given the limited availability of underwater weighing and the overall expense of dual energy x-ray absorptiometry (DEXA), estimates of body fat such as bioelectrical impedance analysis (BIA) may be used instead. An alternate representation of the SI, which uses the body weight change as the denominator, can be used. The interpretation of the reviewed data did not change when %D body weight was used as a denominator (data not shown). However, the use of fat loss to normalize VAT loss, may be important for interventions which preserve lean mass during weight loss. Exercise, 21 caffeine and ephedrine, 22 and the emerging b 3 agonists, have all been shown to prevent LBM loss during weight loss in humans or animals. Although the direct measurement of FM is dif®cult and more expensive, it is an important consideration when a clinical trial is designed to target VAT, 23 or when lean mass is likely to be preserved, as with b 3 agonists.
How does the VAT SI provide an advantage over measurement of VAT alone? Within a single study, the raw data for the loss of VAT and the loss of total body fat are available to the investigators for analysis. As a consequence, the absolute loss of VAT, can be adjusted for the loss of body fat. One can then test whether two treatments differ in their ability to promote selective loss of VAT. On the other hand, most studies compare a treatment to placebo and the intervention almost always results in a greater % loss of VAT than % loss of total body fat. As we have demonstrated, virtually all interventions demonstrate à preferential' or`selective' loss of VAT. The SI can then provide a benchmark for comparisons between studies. For example, Schwartz et al stated in 1991 that,``there is a preferential loss of adiposity from central depots following intensive endurance training in older men.'' When one examines the raw data, the absolute loss of VAT in the older men is approximately 35 cm 2 . In the younger men, the loss of VAT is only 11.5 cm 2 . When one simply observes these two values, one would conclude that the older men had a greater loss of VAT than the younger men. However, it is also noteworthy that the older men also lost a greater degree of body fat (712% old vs 78% young). When one takes the greater loss of body fat in the older individuals into account, the SI is almost identical between the two groups (1.6 for the younger men and 1.7 for the older men). When viewed from the perspective of a greater overall body fat loss in the older men, it is then dif®cult to state that the older men had a``preferential loss of adiposity from central depots''. For these reasons we believe that the SI forces one to consider the overall body fat change when groups are compared within studies or between studies.
Conclusions
As new weight loss therapies enter the marketplace, a method for evaluating each for speci®city of VAT loss, is needed. We recommend that studies which use CT or MRI scanning to measure VAT, use either body fat mass loss or weight loss to normalize these data. This ratio, which we call the VAT SI, can be easily calculated and allows for the comparison of different treatment regimens. This method will allow for a better understanding of not only the ef®cacy of the therapy, but also the factors which control mass.
